Axcella Health Analyst Ratings
Axcella Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/16/2022 | 355.58% | SVB Leerink | $6 → $2 | Downgrades | Outperform → Market Perform |
| 12/15/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 11/02/2022 | 1038.95% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 2177.9% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 1722.32% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 1266.74% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 1494.53% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 1950.11% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 2633.49% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 1266.74% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 1038.95% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 3089.07% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 2177.9% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 3544.65% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 2177.9% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 3089.07% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 2177.9% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 5594.76% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 6278.13% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 4455.81% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 2177.9% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 2405.69% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 4455.81% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 5594.76% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/16/2022 | 355.58% | SVB Leerink | $6 → $2 | 评级下调 | 跑赢→市场表现 |
| 12/15/2022 | — | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 11/02/2022 | 1038.95% | 查尔丹资本 | $7 → $5 | 维护 | 买 |
| 10/03/2022 | 2177.9% | HC Wainwright公司 | $8 → $10 | 维护 | 买 |
| 08/03/2022 | 1722.32% | HC Wainwright公司 | $14 → $8 | 维护 | 买 |
| 08/03/2022 | 1266.74% | SVB Leerink | $9 → $6 | 维护 | 跑赢大盘 |
| 05/09/2022 | 1494.53% | 查尔丹资本 | $12 → $7 | 维护 | 买 |
| 03/31/2022 | 1950.11% | SVB Leerink | $10 → $9 | 维护 | 跑赢大盘 |
| 11/16/2021 | 2633.49% | 查尔丹资本 | $10 → $12 | 维护 | 买 |
| 10/12/2021 | 1266.74% | 来宝资本市场 | → $6 | 开始承保 | →跑赢大盘 |
| 09/22/2021 | 1038.95% | 高盛 | $9 → $5 | 评级下调 | 购买→中性 |
| 07/30/2021 | — | 摩根大通 | 评级下调 | 中性→减持 | |
| 07/06/2021 | 3089.07% | HC Wainwright公司 | → $14 | 开始承保 | →购买 |
| 06/03/2021 | 2177.9% | 查尔丹资本 | $16 → $10 | 维护 | 买 |
| 10/27/2020 | 3544.65% | 查尔丹资本 | → $16 | 开始承保 | →购买 |
| 10/26/2020 | 2177.9% | SVB Leerink | → $10 | 假设 | →跑赢大盘 |
| 09/25/2020 | 3089.07% | B.莱利证券 | → $14 | 开始承保 | →购买 |
| 08/06/2020 | 2177.9% | SVB Leerink | $20 → $10 | 维护 | 跑赢大盘 |
| 07/31/2020 | 5594.76% | 派珀·桑德勒 | → $25 | 开始承保 | →超重 |
| 05/28/2020 | 6278.13% | 韦德布什 | → $28 | 开始承保 | →跑赢大盘 |
| 05/18/2020 | 4455.81% | SVB Leerink | $21 → $20 | 维护 | 跑赢大盘 |
| 05/01/2020 | 2177.9% | BTIG | → $10 | 开始承保 | →购买 |
| 11/15/2019 | 2405.69% | 摩根大通 | $20 → $11 | 维护 | 超重 |
| 06/03/2019 | 4455.81% | 摩根大通 | → $20 | 开始承保 | →超重 |
| 06/03/2019 | 5594.76% | 高盛 | → $25 | 开始承保 | →购买 |
What is the target price for Axcella Health (AXLA)?
Axella Health(Axla)的目标价是多少？
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by HC Wainwright & Co. on December 15, 2022. The analyst firm set a price target for $0.00 expecting AXLA to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
安塞拉健康公司(纳斯达克代码：AXLA)的最新目标价是由HC Wainwright&Co.于2022年12月15日报道的。这家分析公司将目标价定为0.00美元，预计Axla将在12个月内下跌(跌幅可能为-100.00%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Axcella Health (AXLA)?
分析师对Axella Health(Axla)的最新评级是多少？
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by HC Wainwright & Co., and Axcella Health downgraded their neutral rating.
分析师对安塞拉健康公司(纳斯达克代码：AXLA)的最新评级由HC Wainwright&Co.提供，安塞拉健康公司下调了其中性评级。
When is the next analyst rating going to be posted or updated for Axcella Health (AXLA)?
Axcell a Health(Axla)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on December 15, 2022 so you should expect the next rating to be made available sometime around December 15, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Axcella Health的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Axcell a Health的上一次评级是在2022年12月15日提交的，因此您应该预计下一次评级将在2023年12月15日左右提供。
Is the Analyst Rating Axcella Health (AXLA) correct?
分析师对Axella Health(Axla)的评级正确吗？
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Axcella Health (AXLA) is trading at is $0.44, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Axcell Health(Axla)评级被下调，目标价为0.00美元至0.00美元。Axella Health(Axla)目前的股价为0.44美元，超出了分析师的预测区间。